OptimizeRx (OPRX) Expected to Announce Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect OptimizeRx to post earnings of $0.25 per share and revenue of $30.36 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

OptimizeRx Stock Performance

OptimizeRx stock opened at $4.58 on Monday. The firm has a 50 day simple moving average of $5.45 and a 200-day simple moving average of $5.98. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $16.31. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. The stock has a market cap of $84.37 million, a price-to-earnings ratio of -3.44 and a beta of 1.31.

Analyst Upgrades and Downgrades

OPRX has been the topic of several recent analyst reports. Stephens initiated coverage on shares of OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective on the stock. Roth Mkm restated a “buy” rating and issued a $16.00 price objective (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Stifel Nicolaus decreased their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. B. Riley decreased their price objective on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. Finally, Lake Street Capital restated a “buy” rating and issued a $11.00 price objective on shares of OptimizeRx in a report on Tuesday, December 24th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.06.

Insiders Place Their Bets

In other OptimizeRx news, CEO William J. Febbo bought 20,000 shares of OptimizeRx stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the acquisition, the chief executive officer now directly owns 601,253 shares in the company, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.10% of the stock is owned by company insiders.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.